by jtcir-auto | Oct 1, 2024 | Press Releases
TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of...
by jtcir-auto | Oct 1, 2024 | Press Releases
TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of...
by jtcir-auto | Sep 23, 2024 | Press Releases
TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of...
by jtcir-auto | Aug 27, 2024 | Press Releases
– Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol – Potent growth hormone release following macimorelin stimulation – Safety of macimorelin confirmed in the pediatric population...
by jtcir-auto | Aug 27, 2024 | Press Releases
– Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol – Potent growth hormone release following macimorelin stimulation – Safety of macimorelin confirmed in the pediatric population...